S&P Futures
3,768.75 -20.75 (-0.55%) Dow Futures
30,624.00 -157.00 (-0.51%) Nasdaq Futures
11,449.50 -80.00 (-0.69%) Russell 2000 Futures
1,696.50 -11.50 (-0.67%) Crude Oil
108.69 +2.93 (+2.77%) Gold
1,789.20 -18.10 (-1.00%)
Grifols, S.A. (GIKLY)
Chart Events
Performance Outlook
| Previous Close | 10.40 |
| Open | 9.52 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 9.25 - 9.52 |
| 52 Week Range | 8.03 - 13.41 |
| Volume | |
| Avg. Volume | 23,524 |
| Market Cap | 12.72B |
| Beta (5Y Monthly) | 0.18 |
| PE Ratio (TTM) | 16.88 |
| EPS (TTM) | 0.55 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.32 (3.09%) |
| Ex-Dividend Date | Jun 03, 2021 |
| 1y Target Est | N/A |
- American City Business Journals
Pharma giant gets rolling on 300-job Clayton expansion that could get even bigger
A multinational company that's already one of the largest employers in the Greater Triangle is taking steps toward a huge expansion that's years in the making.
- PR Newswire
Grifols Procleix Plasmodium Assay receives CE mark, a first for malaria blood screening
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and the development of innovative diagnostic solutions, today announced that its Procleix Plasmodium Assay has obtained the CE mark, the first for an automated nucleic acid test (NAT) system specifically validated for screening blood donors for malaria.
- Motley Fool
Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond
On top of those pluses, these three companies all have a history of offering above-average dividends, making them solid long-term value bargains. Takeda is a Japanese biopharmaceutical company that focuses on gastroenterology, oncology, neuroscience, and rare diseases. The company's stock is up more than 9% this year, currently trading at just shy of $15.
